Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3281359 | 1.00 | ACE (0.48) | ACESMN1; SMN2L3MBTL1CYP3A4TSHR | |
| SCHEMBL8430471 | 0.83 | ACE (0.35) | ACESMN1; SMN2L3MBTL1CYP3A4TSHR | |
| SCHEMBL13383861 | 0.82 | KDM4E (0.39) | ACEL3MBTL1TSHRTDP1MAPT | |
| SCHEMBL7562792 | 0.81 | PLA2G10 (0.36) | ACE | |
| SCHEMBL23973988 | 0.81 | L3MBTL1 (0.37) | ACESMN1; SMN2L3MBTL1TSHRKMT2A | |
| SCHEMBL7713390 | 0.79 | ACE (0.57) | ACESMN1; SMN2L3MBTL1 | |
| SCHEMBL7566141 | 0.79 | KMT2A (0.35) | ACESMN1; SMN2L3MBTL1CYP3A4TSHR | |
| SCHEMBL19185893 | 0.72 | ACE (0.34) | ACESMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL8240625 | 0.71 | ACE (0.39) | ACETSHRKMT2A | |
| SCHEMBL8431892 | 0.71 | ACE (0.59) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486315-B2 | RECRYSTALLIZING MERCAPTOALKANOYLAMINO LACTAM ACID UNDER BASIC CONDITIONS USING AN AGENT THAT MINIMIZES AMOUNT OF DISULFIDES | BRISTOL-MYERS SQUIBB CO. | 2002-11-26 | — | — | US | disclosed |
| US-6444810-B1 | ACYLMERCAPTOALKANOYLAMINO LACTAM ESTERS OR ACIDS ARE CONVERTED TO THE CORRESPONDING MERCAPTOALKANOYLAMINO LACTAM ESTER OR ACID UNDER BASIC CONDITIONS USING AN AGENT THAT MINIMIZES AMOUNT OF DISULFIDES | BRISTOL-MYERS SQUIBB CO. | 2002-09-03 | — | — | US | disclosed |
| US-20020086995-A1 | Recrystallization processes | KRONENTHAL DAVID R (US) | 2002-07-04 | — | — | US | disclosed |
| US-6340752-B1 | CLEAVAGE OF THIO GROUP FROM CARBONYL AND CONVERSION TO LACTAM ESTER | BRISTOL-MYERS SQUIBB CO. | 2002-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086995-A1 | Recrystallization processes | MPST, TST, SLC39A11 | ACE 1296/4885SMN1; SMN2 2789/4885L3MBTL1 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.